The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).
 
Minetta C. Liu
Research Funding - Eisai (Inst); GRAIL (Inst); Janssen Diagnostics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Genomic Health; GRAIL; ION Pharma (Inst); Menarini Silicon Biosystems; Merck; Pfizer
 
David W. Hillman
No Relationships to Disclose
 
Ashley Elizabeth Frith
No Relationships to Disclose
 
Alan P. Lyss
No Relationships to Disclose
 
Douglas Jay Weckstein
No Relationships to Disclose
 
Alvaro Moreno-Aspitia
Stock and Other Ownership Interests - Merrimack
Patents, Royalties, Other Intellectual Property - Royalties from the development of a xenograft model. Royalties were assigned to go to my institution and not personally
 
Nguyet Le-Lindqwister
No Relationships to Disclose
 
Claudine Isaacs
Honoraria - AstraZeneca; Genentech/Roche; Pfizer
Consulting or Advisory Role - AstraZeneca; Context Therapeutics; Genentech/Roche; Novartis; Pfizer; Puma Biotechnology; Seagen
Speakers' Bureau - AstraZeneca; Genentech; Pfizer
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier - Editor of Book; McGraw Hill Publishing; UpToDate - Wolters Kluwer - Author of chapters
 
Donald B. Wender
No Relationships to Disclose
 
DeQuincy Andrew Lewis
No Relationships to Disclose
 
John T. Cole
No Relationships to Disclose
 
Anthony John Jaslowski
No Relationships to Disclose
 
Kendrith M. Rowland
No Relationships to Disclose
 
Thomas H. Openshaw
No Relationships to Disclose
 
Bret Edward Buckley Friday
No Relationships to Disclose
 
Gini F. Fleming
Honoraria - Curio Science
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Forty Seven (Inst); Genentech (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Leap Therapeutics (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
(OPTIONAL) Uncompensated Relationships - TTC Oncology
 
Erik Asmus
No Relationships to Disclose
 
Lauren J. Rogak
No Relationships to Disclose
 
Ethan M. Basch
Consulting or Advisory Role - Carevive Systems; Navigating Cancer; SIVAN Innovation
Other Relationship - American Society of Clinical Oncology; Centers for Medicare and Medicaid Services; JAMA-Journal of the American Medical Association; National Cancer Institute; Patient-Centered OUtcomes Research Institute (PCORI)
 
Amylou C. Dueck
Consulting or Advisory Role - Bayer; Phytogine